Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up, Cell Culture Innovation
The Go-to Podcast for Biotech Scientists Who Want to Master Biopharma CMC Development and Biomanufacturing.
**TOP 10 LIFE SCIENCES PODCAST**
Are you ready to simplify bioprocess development and scale with confidence to reduce time to market?
Are you feeling overwhelmed by the complexity and guesswork of biologics development and biomanufacturing?
Do you wish you had more time to enjoy the beauty of science, without worrying about failing your cell culture process development and commercialization?
There's a way to simplify and streamline so you can remove complexity, skip trials and errors, deliver your groundbreaking therapy to clinics and market without delay, and still enjoy every single step.
I'm David Brühlmann, a biotech entrepreneur and strategic advisor who partners with C-level biopharma leaders to tackle one of our industry's biggest challenges: reducing manufacturing costs to make lifesaving therapies accessible to more patients worldwide.
Through engaging conversations with industry pioneers and practical insights from the trenches, this podcast tackles the critical challenges in bioprocess CMC development and manufacturing of recombinant proteins and cell and gene therapy products. We cut through the complexity so you can:
- Master bioprocess development with confidence and clarity
- Excel at scale-up and manufacturing of biologics
- Transform your innovative therapy and manufacturing technology into market-ready solutions faster
- Optimize manufacturing costs without compromising quality
- Make data-driven decisions that reduce the risk of failure
I can’t wait to help you do biotech the smart way.
Grab a cup of coffee and your favorite notebook and pen. Now is the time to take your bioprocessing game to the next level.
Ready to transform your biomanufacturing journey? Let's dive in!
Next Steps:
Book a free call to reduce biomanufacturing costs and make lifesaving therapies more accessible: https://bruehlmann-consulting.com/call
🧬 Ready to accelerate your IND timeline? Get the proven CMC Dashboard that's guided successful mAb programs from chaos to submission: https://stan.store/SmartBiotech/p/cmc-dashboard-for-biotech-founders
Accelerate biologics development with expert guidance: https://bruehlmann-consulting.com
Visit the Website: https://smartbiotechscientist.com
Email us: hello@bruehlmann-consulting.com
Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up, Cell Culture Innovation
179: How Mesenchymal Stromal Cells Are Transforming Care for Diabetes and Autoimmune Diseases with Lindsay Davies - Part 1
The key to conquering autoimmune diseases and type 1 diabetes may lie not in replacing lost cells, but in retraining the immune system using cells already within the body.
Biotech is increasingly exploring stem cell therapies, but a quieter revolution is brewing: stromal cell therapy. These master “coordinators” aren’t about rebuilding tissues molecule by molecule - instead, they orchestrate an anti-inflammatory response, offering new hope for conditions once considered incurable.
In this episode of the Smart Biotech Scientist Podcast, host David Brühlmann speaks with Lindsay Davies, a leading expert in advanced therapies. She is the CSO at NextCell Pharma, consultant at CellTherEx, and co-founder of QVance, a QC analytics provider for ATMPs. Recently elected Vice President Elect for Europe at ISCT, Lindsay also chairs its European Industry Committee and serves on multiple task forces. With over 20 years bridging academia and industry, she’s helped shape the full lifecycle of cell-based therapies, from development to commercialization.
Here are three reasons why you can’t miss this episode:
- Stromal Cells - The Unsung Heroes: Discover the essential distinction between stem cells (the “builders”) and stromal cells (the “coordinators”), and how harnessing the latter’s unique immune-modulatory powers is unlocking treatments for diabetes, COVID-19, and autoimmune diseases.
- A Manufacturing Mindset Shift: Lindsay explains why scaling out cell therapies defies the “plug-and-play” approaches of traditional biologics manufacturing. With cell quality so sensitive to environmental shifts, the key lies in process simplicity, early regulatory collaboration, and deep biological understanding - especially when donor variability enters the mix.
- Allogeneic Therapies Made Real: Thanks to umbilical cord-derived stromal cells, treatments can be manufactured at scale, stored frozen, and delivered on demand - no patient matching required. The result? Outpatient infusions, no side effects, and effects lasting up to five years, dramatically simplifying lives for those with chronic inflammatory conditions.
Ready to rethink how cell therapies are changing medicine - and what it could mean for your bioprocessing strategy? Hit play and find out how Lindsay Davis is redefining what’s possible in advanced therapy manufacturing.
Connect with Lindsay Davis:
LinkedIn: www.linkedin.com/in/lindsay-c-davies
Website: www.nextcellpharma.com
If you're interested in breakthroughs in cell therapy, here's what some of our previous guests have shared from the front lines of innovation:
- Episodes 105-106: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver Kraemer
- Episodes 109-110: Spinning Like Earth: Designing Low-Shear Bioreactors for Better Cell Culture with Olivier Detournay
- Episodes 125-126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei
Next step:
Book a free consultation to help you get started on any questions you may have about bioprocess development: https://bruehlmann-consulting.com/call
🧬 Ready to eliminate CMC chaos and hit your IND timeline with absolute certainty? Get the complete Notion CMC Dashboard at https://stan.store/SmartBiotech/p/cmc-dashboard-for-biotech-founders - the proven roadmap that's guided successful mAb programs to hit their IND submission deadlines.